Bruker Corporation — FY 2014 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2014; it is not a standalone fourth-quarter filing. Bruker designs and manufactures scientific instruments and related products. Bruker Scientific Instruments (BSI) generated about 93% of revenue; Bruker Energy & Supercon Technologies (BEST) accounted for the remainder.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 | Change |
|---|---|---|---|
| Revenue | $1,808.9 million | $1,839.4 million | Down 1.7% |
| Gross profit / margin | $763.3 million / 42.2% | $805.2 million / 43.8% | Margin down 1.6 points |
| Operating income / margin | $105.4 million / 5.8% | $148.2 million / 8.1% | Down 28.9% |
| Net income attributable to Bruker | $56.7 million | $80.1 million | Down 29.2% |
| Diluted EPS | $0.33 | $0.48 | Down $0.15 |
| Cash from operations | $114.3 million | $145.0 million | Down $30.7 million |
- Revenue excluding foreign exchange and acquisition/divestiture effects declined 0.4%. Currency effects reduced revenue by approximately $25.4 million. BSI revenue fell 2.0% to $1,674.6 million; BEST revenue rose 3.7% to $152.9 million.
- Profitability weakened amid lower gross margin, foreign-exchange pressure, restructuring and impairment charges, and a higher effective tax rate (41.2% versus 34.3%). FY 2014 included $36.1 million of restructuring costs and $11.5 million of asset impairments.
- Cash and cash equivalents were $319.5 million and short-term investments were $178.0 million at year-end, together $497.5 million. Total debt was $355.0 million; management reported $218.2 million of available revolving capacity. Working capital was $783.6 million.
- Operating cash flow was $114.3 million. Investing cash outflow was $201.9 million, principally reflecting $192.6 million of net purchases of short-term investments and $30.7 million of net capital expenditures. Financing cash inflow was $6.7 million.
- About $460.7 million, or 93%, of cash, cash equivalents and short-term investments was held by foreign subsidiaries. The company stated it did not anticipate needing to repatriate foreign earnings under current plans.
- Debt covenants were met at year-end. The revolving credit agreement matures in May 2016; senior notes total $240.0 million, with maturities from 2017 through 2024. The company reported leverage and interest-coverage ratios of 1.4 and 12.3 under the note agreement.
Material changes and fourth-quarter results
- Annual revenue declined after growth in 2013. Management cited weaker academic and government NMR orders, softness in semiconductor, data storage and microelectronics markets, Japanese competitors’ currency-driven pricing advantage, export-license delays, and divestitures and restructuring in the former Chemical and Applied Markets (CAM) division.
- BSI’s system revenue declined to $1,316.5 million from $1,385.1 million, while aftermarket revenue increased to $358.1 million from $324.4 million.
- FY 2014 fourth-quarter revenue was $508.0 million versus $552.1 million in Q4 2013; operating income was $44.5 million versus $61.0 million, and net income attributable to Bruker was $26.1 million versus $35.2 million. The fourth quarter remained the company’s largest revenue quarter, consistent with its historical seasonality.
- At year-end, system backlog was approximately $877 million, down from $921 million a year earlier; Bruker expected to fill about 78% of the 2014 year-end backlog during 2015.
Outlook, risks, contingencies and unusual items
- Management expected foreign exchange to negatively affect 2015 revenue and overall results, but did not quantify the expected impact. The filing provides no specific consolidated revenue or EPS guidance.
- Management expected $25–$30 million of 2015 expenses for restructuring and outsourcing initiatives, approximately $45 million in 2015 capital spending, and about $14 million of 2015 interest expense. CAM actions were expected to generate annual savings of $15–$20 million once substantially complete by the end of Q1 2015. Further BioSpin restructuring was expected to reduce headcount by approximately 9% once completed.
- Following changes to its Swiss pension plan in Q1 2015, Bruker expected 2015 pension expense to increase by about $16 million, including a one-time, non-cash settlement charge of about $10 million.
- On December 15, 2014, Bruker settled the SEC’s FCPA books-and-records and internal-controls matter through a cease-and-desist order and paid $2.4 million in disgorgement, interest and penalty. The company said investigative matters were complete as of year-end. It recorded $3.2 million of related legal and professional fees in 2014; the filing also reports approximately $24.7 million in fees associated with the investigation and settlement.
- Key risks include foreign-exchange volatility, customer and government research funding, capital-spending cycles, competition and technology shifts, restructuring execution, reliance on limited or single-source suppliers, raw-material and helium availability, export licensing, international operations and compliance, and debt-service and covenant obligations. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether the 2015 restructuring savings materialized and how actual restructuring costs and headcount reductions compared with management’s estimates.
- How much of the backlog converted to revenue, and whether NMR demand, semiconductor-related markets and export-license timing improved.
- The actual impact of currency movements on revenue, gross margin and cash flow, including the company’s exposure to Japanese-yen sales.
- Whether operating cash flow and liquidity remained adequate given the concentration of cash overseas, debt maturities and revolving-credit availability.
- The realized 2015 pension expense increase and settlement charge, and any subsequent developments in tax contingencies or supplier constraints.